CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

Abstract Background Our previous studies have identified CA916798 as a chemotherapy resistance-associated gene in lung cancer. However, the histopathological relevance and biological function of CA916798 in lung adenocarcinoma (LUAD) remains to be delineated. In this study, we further investigated a...

Full description

Bibliographic Details
Main Authors: Jian He, Xi Lan, Xiayan Liu, Caixia Deng, Hu Luo, Yan Wang, Ping Kang, Zhijian Sun, Lintao Zhao, Xiangdong Zhou
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
Lung adenocarcinoma
CA916798
CCNB1
G2/M phase
Gefitinib resistance
Online Access:https://doi.org/10.1186/s12885-023-10735-3

Internet

https://doi.org/10.1186/s12885-023-10735-3

Similar Items